Danilon Equidos 1.5 g Granules for Top Dressing

Land: Storbritannien

Sprog: engelsk

Kilde: VMD (Veterinary Medicines Directorate)

Aktiv bestanddel:

Suxibuzone

Tilgængelig fra:

Ecuphar Veterinaria S.L.U.

ATC-kode:

QM01AA90

INN (International Name):

Suxibuzone

Lægemiddelform:

Granules

Recept type:

POM-V - Prescription Only Medicine – Veterinarian

Terapeutisk gruppe:

Horses

Terapeutisk område:

Anti Inflammatory NSAID

Autorisation status:

Authorized

Autorisation dato:

2001-08-02

Produktets egenskaber

Revised: March 2022
AN: 02928/2021
Page 1 of 6
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Danilon Equidos 1.5 g Granules for top dressing
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 10 g sachet contains ACTIVE SUBSTANCE
G
Suxibuzone (microencapsulated) 1.5
EXCIPIENT(S):
Quinoline yellow (E 104)
0.0025
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Granules for top dressing use.
Yellow and odourless granules.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Equines.
4.2
INDICATIONS FOR USE
Treatment of pain and inflammation associated with musculo-skeletal
conditions
in the horse _eg_ osteoarthritic conditions, bursitis, laminitis and
soft tissue
inflammation.
4.3
CONTRA-INDICATIONS
Do not administer to animals with renal, hepatic or cardiac disorders;
where
there is the possibility of gastro-intestinal ulceration or bleeding,
or where there is
evidence of a blood dyscrasia or hypersensitivity to the product.
Avoid use in dehydrated, hypovolemic or hypotensive animals as there
is an
increased risk of renal failure.
Revised: March 2022
AN: 02928/2021
Page 2 of 6
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
Do not administer to horses prior to taking part in a competition.
During treatment of very young animals (less than 12 weeks) where
development of
their hepatic or renal function may be incomplete, or in aged animals
which may have
these functions impaired, as well as in ponies, additional risk may be
involved. In
these cases, doses should be accurately calculated and patients
monitored closely.
During treatment, do not restrict the consumption of water. Avoid use
in any
dehydrated, hypovolaemic or hypotensive animals as there may be an
increased risk
of renal failure.
NSAIDs can cause inhibition of phagocytosis and hence, in the
treatment of
inflammatory conditions associated with bacterial infections
appropriate antimicrobial
therapy should be instigated.
4.5
SPECIAL PRECAUTIONS FOR USE
I.
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
During treatment do not